Celeras Dx’ patient monitoring delivers speedy status reports on biomarkers which are associated with clinical decisions to be made during treatment of serious infection - especially sepsis. The tests have been conceived for the periodic testing of patients in such a manner that the minimum use of samples is involved and a simple and rapid analysis is available. The aim is to deliver a “picture” of the inflammation and organ status which is as complete as possible and which quickly indicates any deterioration in the condition of the patient.
The sample is pipetted into the hybcell (=cartridge). The sample dissolves a reaction mix lyophilised within the cartridge. The hybcells are transferred to the hyborg – the fully automatic device. The measured values are interpreted by the software and presented within the measurement range as quantitative results in a tabulated report.
xA panel (Research Use Only):
hybcell PM Blood xA
Multiplexed Immuno-test of 9 markers
12 x hybcell
at MISK Global Forum in Riyadh, Saudi Arabia (12-14 November, 2019).
at DxPx Conference in Duesseldorf, Germany (18 November, 2019).
at ECCMID in Paris, France (18-21 April, 2019).
Celeras Dx - Part of Cube Dx GmbH | Westbahnstrasse 55 | 4300 St. Valentin (Austria) | firstname.lastname@example.org